The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KYMR | +99.53% | +45.05% | +7.72% | +161% |
| S&P | +13.01% | +86.49% | +13.27% | +101% |
Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.
| Q3 2025 | YOY Change | |
|---|---|---|
| Revenue | $2.76M | -26.1% |
| Gross Profit | $0.62M | -64.7% |
| Gross Margin | 22.25% | -24.3% |
| Market Cap | $4.05B | 34.1% |
| Market Cap / Employee | $17.99M | 10.9% |
| Employees | 225 | 0.0% |
| Net Income | -$82.18M | -31.5% |
| EBITDA | -$86.52M | -23.4% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q3 2025 | YOY Change | |
|---|---|---|
| Net Cash | $112.95M | 2.0% |
| Accounts Receivable | $0.00M | -100.0% |
| Inventory | 0 | 0.0% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $70.25M | -6.8% |
| Short Term Debt | $13.74M | 6.9% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -27.62% | -6.5% |
| Return On Invested Capital | -24.56% | 10.8% |
| Q3 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$27.29M | 45.4% |
| Operating Free Cash Flow | -$27.11M | 46.0% |
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 2.92 | 2.13 | 3.61 | 4.11 | 19.78% |
| Price to Sales | 68.36 | 37.25 | 78.52 | 112.98 | 174.58% |
| Price to Tangible Book Value | 2.92 | 2.13 | 3.61 | 4.11 | 19.78% |
| Enterprise Value to EBITDA | -35.76 | -25.10 | -35.54 | -52.24 | 16.61% |
| Return on Equity | -36.4% | -32.2% | -33.3% | -32.1% | 23.45% |
| Total Debt | $87.76M | $86.33M | $85.71M | $84.00M | -4.80% |
No podcast episodes available.
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
